In tumor formation experiments, we observed that interference with downstream PGK1 expression almost completely reversed the tumorigenicity caused by the downregulation of LHX9 expression, suggesting that treatment with inhibitors of PGK1 is highly likely to benefit patients with glioma. The gene discussed is PGK1; the disease is neoplasm.